# LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer

> **NCT00010270** · PHASE1 · UNKNOWN · sponsor: **University Hospital Freiburg** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Cancer
- Esophageal Cancer
- Gastric Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** LMB-9 immunotoxin

## Key facts

- **NCT ID:** NCT00010270
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010270, "LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00010270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*